Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus TETRACHEL.
ACTICLATE CAP vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic